The vaginal and gastrointestinal microbiomes in gynecologic cancers: A review of applications in etiology, symptoms and treatment

Dana Chase, Alison Goulder, Frederic Zenhausern, Bradley Monk, Melissa Herbst-Kralovetz

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The human microbiome is the collection of microorganisms in the body that exist in a mutualistic relationship with the host. Recent studies indicate that perturbations in the microbiome may be implicated in a number of diseases, including cancer. More specifically, changes in the gut and vaginal microbiomes may be associated with a variety of gynecologic cancers, including cervical cancer, uterine cancer, and ovarian cancer. Current research and gaps in knowledge regarding the association between the gut and vaginal microbiomes and the development, progression, and treatment of gynecologic cancers are reviewed here. In addition, the potential use of probiotics to manage symptoms of these gynecologic cancers is discussed. A better understanding of how the microbiome composition is altered at these sites and its interaction with the host may aid in prevention, optimization of current therapies, development of new therapeutic agents and/or dosing regimens, and possibly limit the side effects associated with cancer treatment.

Original languageEnglish (US)
Pages (from-to)190-200
Number of pages11
JournalGynecologic Oncology
Volume138
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Microbiota
Neoplasms
Uterine Neoplasms
Second Primary Neoplasms
Probiotics
Uterine Cervical Neoplasms
Ovarian Neoplasms
Gastrointestinal Microbiome
Therapeutics
Research

Keywords

  • Bacterial therapeutics
  • Commensal microbiota
  • Dysbiosis
  • Epithelial barrier function
  • Probiotics
  • Quality of life
  • Radiation and chemotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

The vaginal and gastrointestinal microbiomes in gynecologic cancers : A review of applications in etiology, symptoms and treatment. / Chase, Dana; Goulder, Alison; Zenhausern, Frederic; Monk, Bradley; Herbst-Kralovetz, Melissa.

In: Gynecologic Oncology, Vol. 138, No. 1, 01.07.2015, p. 190-200.

Research output: Contribution to journalArticle

@article{b87d33a4a1cb49dcb5f2eae9584d35e8,
title = "The vaginal and gastrointestinal microbiomes in gynecologic cancers: A review of applications in etiology, symptoms and treatment",
abstract = "The human microbiome is the collection of microorganisms in the body that exist in a mutualistic relationship with the host. Recent studies indicate that perturbations in the microbiome may be implicated in a number of diseases, including cancer. More specifically, changes in the gut and vaginal microbiomes may be associated with a variety of gynecologic cancers, including cervical cancer, uterine cancer, and ovarian cancer. Current research and gaps in knowledge regarding the association between the gut and vaginal microbiomes and the development, progression, and treatment of gynecologic cancers are reviewed here. In addition, the potential use of probiotics to manage symptoms of these gynecologic cancers is discussed. A better understanding of how the microbiome composition is altered at these sites and its interaction with the host may aid in prevention, optimization of current therapies, development of new therapeutic agents and/or dosing regimens, and possibly limit the side effects associated with cancer treatment.",
keywords = "Bacterial therapeutics, Commensal microbiota, Dysbiosis, Epithelial barrier function, Probiotics, Quality of life, Radiation and chemotherapy",
author = "Dana Chase and Alison Goulder and Frederic Zenhausern and Bradley Monk and Melissa Herbst-Kralovetz",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.ygyno.2015.04.036",
language = "English (US)",
volume = "138",
pages = "190--200",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The vaginal and gastrointestinal microbiomes in gynecologic cancers

T2 - A review of applications in etiology, symptoms and treatment

AU - Chase, Dana

AU - Goulder, Alison

AU - Zenhausern, Frederic

AU - Monk, Bradley

AU - Herbst-Kralovetz, Melissa

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The human microbiome is the collection of microorganisms in the body that exist in a mutualistic relationship with the host. Recent studies indicate that perturbations in the microbiome may be implicated in a number of diseases, including cancer. More specifically, changes in the gut and vaginal microbiomes may be associated with a variety of gynecologic cancers, including cervical cancer, uterine cancer, and ovarian cancer. Current research and gaps in knowledge regarding the association between the gut and vaginal microbiomes and the development, progression, and treatment of gynecologic cancers are reviewed here. In addition, the potential use of probiotics to manage symptoms of these gynecologic cancers is discussed. A better understanding of how the microbiome composition is altered at these sites and its interaction with the host may aid in prevention, optimization of current therapies, development of new therapeutic agents and/or dosing regimens, and possibly limit the side effects associated with cancer treatment.

AB - The human microbiome is the collection of microorganisms in the body that exist in a mutualistic relationship with the host. Recent studies indicate that perturbations in the microbiome may be implicated in a number of diseases, including cancer. More specifically, changes in the gut and vaginal microbiomes may be associated with a variety of gynecologic cancers, including cervical cancer, uterine cancer, and ovarian cancer. Current research and gaps in knowledge regarding the association between the gut and vaginal microbiomes and the development, progression, and treatment of gynecologic cancers are reviewed here. In addition, the potential use of probiotics to manage symptoms of these gynecologic cancers is discussed. A better understanding of how the microbiome composition is altered at these sites and its interaction with the host may aid in prevention, optimization of current therapies, development of new therapeutic agents and/or dosing regimens, and possibly limit the side effects associated with cancer treatment.

KW - Bacterial therapeutics

KW - Commensal microbiota

KW - Dysbiosis

KW - Epithelial barrier function

KW - Probiotics

KW - Quality of life

KW - Radiation and chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84931568592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931568592&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2015.04.036

DO - 10.1016/j.ygyno.2015.04.036

M3 - Article

VL - 138

SP - 190

EP - 200

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -